Data at EAHAD 2021 Highlight Value of Takedas Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
ABS120, ABS185]. About Hemophilia Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood. 4 Hemophilia A is more common than hemophilia B; in 2018, hemophilia A affects about 173,711 people, whereas hemophilia B affects about 34,289 people worldwide. 5 People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment. 6 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or p...
Source: financialbuzz.com
